Cargando…

Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis

BACKGROUND: Many trials are evaluating therapies for men with metastatic hormone-sensitive prostate cancer (mHSPC). OBJECTIVE: To systematically review trials of prostate radiotherapy. DESIGN, SETTING, AND PARTICIPANTS: Using a prospective framework (framework for adaptive meta-analysis [FAME]), we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burdett, Sarah, Boevé, Liselotte M., Ingleby, Fiona C., Fisher, David J., Rydzewska, Larysa H., Vale, Claire L., van Andel, George, Clarke, Noel W., Hulshof, Maarten C., James, Nicholas D., Parker, Christopher C., Parmar, Mahesh K., Sweeney, Christopher J., Sydes, Matthew R., Tombal, Bertrand, Verhagen, Paul C., Tierney, Jayne F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Science 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6575150/ https://www.ncbi.nlm.nih.gov/pubmed/30826218 http://dx.doi.org/10.1016/j.eururo.2019.02.003

Ejemplares similares

What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis
por: Vale, C L, et al.
Publicado: (2018)

Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data
por: Vale, Claire L, et al.
Publicado: (2016)

The value of evidence synthesis in randomised controlled trial (RCT) design, conduct and analysis: MRC clinical trials unit (CTU) at UCL experience
por: Tierney, Jayne F, et al.
Publicado: (2015)

Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis
por: Rydzewska, Larysa H.M., et al.
Publicado: (2017)

A framework for prospective, adaptive meta-analysis (FAME) of aggregate data from randomised trials
por: Tierney, Jayne F., et al.
Publicado: (2021)

Duplicated network meta-analysis in advanced prostate cancer: a case study and recommendations for change
por: Fisher, David J., et al.
Publicado: (2022)

Assessing and improving the reliability of meta-analyses of hazard ratios derived from published time-to-event data
por: Tierney, Jayne, et al.
Publicado: (2013)

Sharing individual participant data: through a systematic reviewer lens
por: Rydzewska, Larysa H. M., et al.
Publicado: (2022)

The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDE’s “M1|RT Comparison”
por: Ali, Adnan, et al.
Publicado: (2020)

Should Tyrosine Kinase Inhibitors Be Considered for Advanced Non–Small-Cell Lung Cancer Patients With Wild Type EGFR? Two Systematic Reviews and Meta-Analyses of Randomized Trials()
por: Vale, Claire L., et al.
Publicado: (2015)

Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial
por: Ali, Adnan, et al.
Publicado: (2021)

Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial
por: Sydes, Matthew R, et al.
Publicado: (2009)

Practical methods for incorporating summary time-to-event data into meta-analysis
por: Tierney, Jayne F, et al.
Publicado: (2007)

Radiotherapy is the Preferred Primary Tumor Treatment in Oligometastatic Prostate Cancer
por: van Moorselaar, R. Jeroen A., et al.
Publicado: (2022)

Comparison of aggregate and individual participant data approaches to meta-analysis of randomised trials: An observational study
por: Tierney, Jayne F., et al.
Publicado: (2020)

Chemoprevention of prostate cancer with nutrients and supplements
por: Van Poppel, Hendrik, et al.
Publicado: (2011)

What is the Need for Prostatic Biomarkers in Prostate Cancer Management?
por: Spahn, Martin, et al.
Publicado: (2015)

Estimating the Impact of Randomised Control Trial Results on Clinical Practice: Results from a Survey and Modelling Study of Androgen Deprivation Therapy plus Radiotherapy for Locally Advanced Prostate Cancer
por: South, Annabelle, et al.
Publicado: (2016)

Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data
por: Clarke, Caroline S., et al.
Publicado: (2022)

Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials
por: Dearnaley, David P, et al.
Publicado: (2009)

Cardiovascular risk during hormonal treatment in patients with prostate cancer
por: Van Poppel, Hein, et al.
Publicado: (2011)

Analysis of survival data from trials with non-proportional hazards: an empirical comparison of methods
por: Royston, Patrick, et al.
Publicado: (2013)

Parenteral oestrogen in the treatment of prostate cancer: a systematic review
por: Norman, G, et al.
Publicado: (2008)

Accumulation of copy number alterations and clinical progression across advanced prostate cancer
por: Grist, Emily, et al.
Publicado: (2022)

Modern Detection of Prostate Cancer's Bone Metastasis: Is the Bone Scan Era Over?
por: Tombal, Bertrand, et al.
Publicado: (2012)

Intravesical protrusion of giant median prostatic lobe: A case report
por: Duijn, M., et al.
Publicado: (2022)

Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial
por: Parker, Chris C., et al.
Publicado: (2022)

Optimising TNM Staging of Patients with Prostate Cancer Using WB-MRI
por: Pasoglou, Vassiliki, et al.
Publicado: (2016)

A Systematic Review and Recommendation for Reporting of Surrogate Endpoint Evaluation Using Meta-analyses
por: Xie, Wanling, et al.
Publicado: (2019)

The need for a cultural shift from two-arm to multi-arm RCTS
por: Sydes, Matthew R, et al.
Publicado: (2013)

A framework for the design and analysis of phase III randomised trials in uncommon diseases
por: Parmar, Mahesh, et al.
Publicado: (2015)

Measuring impact of systematic reviews using individual participant data: evidence from clinical guidelines
por: Vale, Claire, et al.
Publicado: (2013)

How individual participant data meta-analyses have influenced trial design, conduct, and analysis
por: Tierney, Jayne F., et al.
Publicado: (2015)

Hormones and prostate carcinogenesis: Androgens and estrogens
por: Bosland, Maarten C., et al.
Publicado: (2011)

Treatment patterns and characteristics of European patients with castration-resistant prostate cancer
por: Sternberg, Cora N, et al.
Publicado: (2013)

Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion
por: Body, Jean-Jacques, et al.
Publicado: (2018)

Synergistic interaction of benign prostatic hyperplasia and prostatitis on prostate cancer risk
por: Hung, S-C, et al.
Publicado: (2013)

Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations
por: Crawford, E. David, et al.
Publicado: (2018)

Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics
por: Bowden, Jack, et al.
Publicado: (2011)

Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: data from PREVAIL and AFFIRM trials
por: Saad, F, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_v74n3vlr5e6nqlbr6e4p7j9qrt